Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.

Riccardo MarconciniLuca GalliAndrea AntonuzzoSimona BursiClaudia RoncellaGabriella FontaniniElisa SensiAlfredo Falcone

Published in: Experimental hematology & oncology (2017)

This case report shows that trametinib could be a valid therapeutic option in patients with metastatic melanoma harboring the rare BRAF K601E mutation.

Keyphrases

wild type
case report
metastatic colorectal cancer
squamous cell carcinoma
small cell lung cancer
pi k akt
signaling pathway